G. Desantis

发表

CD14 positive cells accelerate hematopoietic stem cell engraftment

L. Antolini, M. Serafini, F. Dazzi, 2022, Bone Marrow Transplantation.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

S. Bicciato, J. Galon, C. Ries, 2016, Cancer cell.

Complexity and Challenges in Defining Myeloid-Derived Suppressor Cells

V. Bronte, S. Mandruzzato, I. Marigo, 2014, Cytometry. Part B, Clinical cytometry.

Complexity and challenges in defining myeloid-derived suppressor cells.

V. Bronte, S. Mandruzzato, I. Marigo, 2014, Cytometry. Part B, Clinical cytometry.

Immune tolerance to tumor antigens occurs in a specialized environment of the spleen.

J. Ochando, S. Ugel, V. Bronte, 2012, Cell reports.

Tumour-Induced Immune Suppression by Myeloid Cells

V. Bronte, S. Zilio, G. Desantis, 2011 .

Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy

M. Lidonnici, L. Naldini, A. Kajaste-Rudnitski, 2017, Stem cell reports.

CD14 positive cells accelerate hematopoietic stem cell engraftment

L. Antolini, M. Serafini, F. Dazzi, 2022, Bone Marrow Transplantation.

High throughput Next-Generation Sequencing Respiratory Viral Panel: A Diagnostic and Epidemiologic Tool for SARS-CoV-2 and Other Viruses.

G. Schroth, R. Kolhe, J. Chen, 2021, medRxiv.

Myeloid cell diversification and complexity: an old concept with new turns in oncology

V. Bronte, S. Mandruzzato, E. Peranzoni, 2011, Cancer and Metastasis Reviews.

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

P. Dessen, B. Janji, S. Chouaib, 2014, The Journal of experimental medicine.

Erratum: T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells (Cancer Cell (2016) 30(3) (377–390)(S1535610816303890)(10.1016/j.ccell.2016.08.004))

S. Bicciato, J. Galon, C. Ries, 2016 .

Therapeutic targeting of myeloid-derived suppressor cells.

S. Ugel, V. Bronte, S. Zilio, 2009, Current opinion in pharmacology.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

S. Bicciato, J. Galon, C. Ries, 2016, Cancer cell.

Inducible nonviral gene expression in the treatment of osteochondral defects.

A. Krüger, A. Imhoff, B. Gansbacher, 2004, Osteoarthritis and cartilage.

Myeloid cell‐based delivery of IFN‐γ reprograms the leukemia microenvironment and induces anti‐tumoral immune responses

L. Naldini, A. Mucci, F. Sanvito, 2021, EMBO molecular medicine.

Expanded circulating hematopoietic stem/ progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis

A. Schulz, C. Carlo-Stella, R. Cusano, 2020, Haematologica.

Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia

P. Rancoita, C. Di Serio, F. Ciceri, 2023, Nature Communications.

miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease

M. Valsecchi, Paola Capasso, D. Silvestri, 2023, Leukemia.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

S. Bicciato, J. Galon, C. Ries, 2016, Cancer cell.

PD-L1 is a novel direct target of HIF-1  , and its blockade under hypoxia enhanced MDSC-mediated T cell

B. Janji, S. Chouaib, M. Noman, 2014 .